Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment.
Luisa FofiClaudia AltamuraGiulia FiorentiniNicoletta BrunelliMarilena MarcosanoBarbanti PieroFabrizio VernieriPublished in: Headache (2022)
Our findings preliminarily demonstrated that patients' migraine improvement after 6 months of galcanezumab treatment could be favorably perceived by caregivers, significantly reducing their distress with better reciprocity within the dyad.